Mission Bio Inc.

46 articles about Mission Bio Inc.

• Mission Bio Announces High Precision Detection of Variants For Tapestri® Platform in NIST Genome Editing Consortium Initial Study

  10/23/2023

  Mission Bio announced today initial results from the National Institute of Standards and Technology (NIST) Genome Editing Consortium's inaugural Interlab Study.

• Mission Bio’s Tapestri Platform Leveraged by Top Academic and Pharma Institutions to Pinpoint Disease-Driving Clones in Multiple Myeloma

  10/12/2023

  Mission Bio announced data underscoring the ability of the Tapestri® Platform to potentially impact cancer therapy by correlating cell surface protein expression of potential therapeutic targets with multiple myeloma (MM) clonal populations.

• Mission Bio Launches Tapestri® Genome Editing Solution for Deeper Analysis of Advanced Therapies

  9/12/2023

  Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, today launched the Tapestri® Genome Editing Solution.

• Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection Applications for Translational Research and Precision Therapeutics

  5/31/2023

  Mission Bio, Inc. today announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications.

• Mission Bio Develops Single-Cell Solution to Address Challenges in Genome Editing

  5/11/2023

  Mission Bio announced today the Tapestri® Genome Editing Solution, an end-to-end product for genome editing analysis.

• Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research

  4/11/2023

  Mission Bio, Inc. today announced that it has entered into an agreement with Fulgent Genetics (NASDAQ: FLGT), a technology-based company with well-established clinical diagnostic and therapeutic development businesses.

• Mission Bio Joins NSF Cell Manufacturing Research Initiative to Advance Cell Therapy Development

  3/28/2023

  Mission Bio has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT), leveraging its Tapestri® Platform to improve analytical assays and cell manufacturing processes.

• Mission Bio's Tapestri® Platform Used to Identify Hidden HIV-infected Cells in Nature Paper

  1/6/2023

  Mission Bio announced a new publication in Nature from researchers at the Ragon Institute of MGH, MIT, and Harvard and Brigham and Women's Hospital using Mission Bio's Tapestri® Platform to identify phenotypic signatures of hidden human immunodeficiency virus 1 -infected immune cells that allow the virus to evade immune response.

• Mission Bio and Abiosciences Partner to Co-develop Bioinformatics for Clinical Research Applications in China

  12/28/2022

  Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers.

• Mission Bio partners with global pharma and academic institutions to demonstrate Tapestri® Platform's translational utility for precision therapeutics at ASH

  12/7/2022

  Mission Bio and academic partners are presenting data from the company's Tapestri® Platform on a range of topics at the 64th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, beginning this weekend in New Orleans, LA.

• Mission Bio's single-cell transduction assay adopted for AVROBIO's gene therapy pipeline

  11/29/2022

  Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the first-time deployment of one single-cell transduction assay across gene therapy company AVROBIO's lysosomal disorder pipeline.

• Mission Bio launches first commercial high-throughput cell therapy assay for measuring vector copy number

  10/6/2022

  Mission Bio, the pioneer in single-cell DNA and multi-omics analysis, announced the availability of the Tapestri® VCN Assay, the first high-throughput commercial single-cell assay to simultaneously quantify VCN and transduction at the level of individual cells.

• Memorial Sloan Kettering researchers present predictive findings from first use of Mission Bio's scMRD assay for AML

  9/22/2022

  Mission Bio, Inc. announced the first findings by researchers using its new Tapestri® Single-cell Multi-omics Measurable Residual Disease assay, as researchers from Memorial Sloan Kettering Cancer Center discovered subclonal co-mutations and immunophenotypic profiles that can distinguish individual cells indicative of future acute myeloid leukemia relapse from others present after treatment.

• Servier leverages Mission Bio's Tapestri® Platform to uncover AML resistance mechanisms in pivotal TIBSOVO® (ivosidenib) clinical trial

  9/15/2022

  Servier to present data at 12th Annual World Clinical Biomarkers & CDx Summit demonstrating the utility of single-cell DNA sequencing with Tapestri ® in clinical development.

• St. Jude Researchers Use Mission Bio's Single-Cell DNA Platform to Elucidate Genomic Landscape of Pediatric ALL

  9/1/2022

  Mission Bio announced new findings from researchers at St. Jude Children's Research Hospital and colleagues in Nature Genetics, using Mission Bio's Tapestri® Platform to help understand how mutations at the single-cell level drive cancer relapse in pediatric acute lymphoblastic cancer.

• IDIBAPS Researchers Discover Genetic Drivers of Clonal Evolution in Leukemia Using Single-Cell DNA Sequencing from Mission Bio

  8/11/2022

  Mission Bio, announced new findings from the lab of Elías Campo, Director of the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) in Barcelona, Spain, which used single-cell DNA sequencing to identify genetic drivers of Richter's syndrome, the unpredictable and often deadly progression from chronic lymphocytic leukemia (CLL) to an aggressive B cell lymphoma.

• Mission Bio Launches Early Access Program for Single-Cell Measurable Residual Disease Detection in Blood Cancers

  7/28/2022

  Mission Bio, Inc. today announced the initial availability of the industry's first assay capable of determining measurable residual disease (MRD) in cancer down to the level of individual cells, launching a new era for the understanding of disease progression.

• Mission Bio Announces Pharma Assay Development Services for Solid Tumor Research

  7/12/2022

  Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the launch of solid tumor assays through its Pharma Assay Development (PAD) services.

• Mission Bio names Josep Carreras Leukaemia Research Institute as First Center of Excellence for Tapestri Platform in Europe

  6/14/2022

  Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced a new Center of Excellence, located at the Josep Carreras Leukaemia Research Institute and led by Manel Esteller, MD, PhD.

• Mission Bio Appoints Todd Druley as Chief Medical Officer

  4/5/2022

  Mission Bio, Inc. today announced the appointment of Todd Druley , MD, PhD.